Company: TXG
Filing Date: 2025-04-14
Form Type: DEF 14A
Source: 0001770787-25-000018
Chunk: 46

Company: 10x Genomics, Inc.
Filing Date: 2025-04-14
Form: DEF 14A
Chunk 46
---
2023 were:

| Named Executive Officer |     | Annual Base Salary as of December 31, 2023 
 ($)                                        |     |         |     | Annual Base Salary as of December 31, 2024 
                                        ($) | Percentage Increase 
 (%)                 |     |      |
|:------------------------|:----|:-------------------------------------------|:----|--------:|:----|-------------------------------------------:|:--------------------|:----|-----:|
| Dr. Saxonov             |     |                                            |     | 551,300 |     |                                    650,000 |                     |     | 17.9 |
| Mr. Taich(1)            |     |                                            |     |     N/A |     |                                    500,000 |                     |     |  N/A |
| Dr. Hindson             |     |                                            |     | 441,000 |     |                                    500,000 |                     |     | 13.4 |
| Mr. Whitaker            |     |                                            |     | 438,900 |     |                                    500,000 |                     |     | 13.9 |
| Mr. McAnear(2)          |     |                                            |     | 419,000 |     |                                    485,000 |                     |     | 15.8 |

(1) Mr. Taich joined the company effective August 12, 2024.

(2) Mr. McAnear separated from the company effective August 30, 2024.

#### Annual Incentive Plan
We maintain an AIP to provide employees, including our named executive officers, with incentives reflecting annual corporate performance and individual contributions. The target award opportunity and the weighting between corporate and individual performance reflect the role of each individual participant. For fiscal year 2024, the compensation committee did not make any changes to the annual bonus award target for named executive officers, in order to balance the base salary market adjustments. Below are the target incentive opportunities and performance weightings for our named executive officers:

#### 10X GENOMICS, INC.462025 PROXY STATEMENT
| Named Executive Officer |     | Target AIP Opportunity 
     (% of Base Salary) 
                   2023 |     |     | Target AIP Opportunity 
     (% of Base Salary) 
                   2024 |     | Corporate Performance Weighting 
                             (%) |     | Individual Performance Weighting 
                              (%) |     |  Actual 2024 
 Bonus Payout